多西环素暴露后预防(DoxyPEP)在真实世界中预防性传播感染:PRIDOX研究
本研究在真实世界环境中评估多西环素暴露后预防(DoxyPEP)对高风险MSM队列中沙眼衣原体(CT)、淋病奈瑟菌(NG)和梅毒(SPL)发病率的影响。876名HIV暴露前预防(PrEP)使用者中197人启动DoxyPEP,结果显示CT和SPL发病率显著下降,NG下降未达统计学显著,未观察到多重耐药菌或耐药NG出现。
要点
- DoxyPEP在常规PrEP照护中接受度高,98.4%为MSM,仅4.5%因故停药。
- 启动DoxyPEP后CT和SPL首次发作发病率显著降低,NG下降无统计学意义。
- 未观察到多重耐药菌或耐药NG emergence,四环素耐药率与未用DoxyPEP者相似。
核心结论
- DoxyPEP在真实世界环境中耐受性良好,显著降低CT和SPL发病率,未观察到多重耐药菌或耐药NG出现。
研究设计与样本
- 前瞻性真实世界队列研究,纳入2023年3月至2024年8月期间就诊的高STI风险HIV PrEP使用者,比较DoxyPEP前后首次CT、NG、SPL发作发病率,采用Cox比例风险模型。
主要发现
- 876名PrEP使用者中197人(22.4%)符合条件并启动DoxyPEP,98.4%为MSM。
- DoxyPEP前后每100人年首次STI发作发病率:CT为31.4 vs 7.8(P=0.0001),NG为41.5 vs 28.9(P=0.1),SPL为21.5 vs 3.2(P=0.0001)。
- DoxyPEP后PCR检测的47例NG感染中14例(29.7%)培养阳性,所有分离株对头孢曲松敏感。
- 四环素耐药率在DoxyPEP使用者与非使用者间相似(42.7% vs 46.3%,P=0.23)。
- 多重耐药菌患病率在基线与48周时相似(10.6% vs 8.2%,P>0.5)。
临床怎么用
- 在高风险MSM的PrEP照护中可考虑提供DoxyPEP以降低CT和SPL发病率,但需持续监测细菌耐药和微生态影响。
局限性
- DoxyPEP对细菌耐药和微生态的影响仍需进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the impact of doxycycline post-exposure prophylaxis (DoxyPEP) on Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG) and syphilis (SPL) incidence in a high-risk MSM cohort in a real-world setting. METHODS: HIV pre-exposure prophylaxis (PrEP) users at high risk of sexually transmitted infections (STIs) seen in our clinic between March 2023 and August 2024 were offered DoxyPEP. The incidence of the first CT, NG and SPL episode was compared between pre-DoxyPEP and post-DoxyPEP periods using Cox proportional hazard models. NG and MDR bacteria cultures were also conducted. RESULTS: Among 876 PrEP users, 197 (22.4%) were eligible and initiated DoxyPEP; 98.4% were MSM. Incidence rates per 100 people per year for the first STI episode in the pre- and post-DoxyPEP periods were: 31.4 and 7.8 (P = 0.0001) for CT, 41.5 and 28.9 (P = 0.1) for NG, and 21.5 and 3.2 (P = 0.0001) for SPL. NG culture was positive in 14 (29.7%) of 47 NG infections detected by PCR in the post-DoxyPEP period. All isolates were sensitive to ceftriaxone, and resistance to tetracyclines was similar to those not on DoxyPEP (42.7% versus 46.3%, P = 0.23). DoxyPEP was discontinued in nine (4.5%) participants. Prevalence of MDR bacteria was similar at baseline and at 48 weeks (10.6% versus 8.2%; P > 0.5). CONCLUSIONS: DoxyPEP was well accepted within routine PrEP care, significantly reducing STI incidence with good tolerance. Our data show its efficacy and safety in real-world settings. The emergence of MDR bacteria or resistant NG was not observed. However, its impact on bacterial resistance and the microbiota requires further evaluation.
引用
- Palacios R, Gómez-Ayerbe C, Martín-Cortés S, et al. Post-exposure prophylaxis with doxycycline (DoxyPEP) to prevent STIs in a real-world setting: the PRIDOX study. J Antimicrob Chemother. 2025. PMID: 41189494. doi:10.1093/jac/dkaf366
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。